Novo Integrated Sciences Inc (NVOS): Full Stock Overview

Novo Integrated Sciences Inc trades under the ticker NVOS, and if you’ve landed on this page you’re probably trying to figure out what the company actually does, why its stock has fallen so far from its Nasdaq days, and whether there’s anything left to watch. Here’s a straight rundown, built from the company’s own filings and recent market data.

What Does Novo Integrated Sciences Do?

Novo Integrated Sciences is a Bellevue, Washington-based healthcare company that runs its business through two main segments: Healthcare Services and Product Manufacturing and Development.

On the services side, the company owns and operates clinics in Canada and the U.S. that offer physiotherapy, chiropractic care, manual manipulation, occupational therapy, and massage therapy. It also provides more specialized care, including acupuncture, functional dry needling, chiropody, and rehabilitation programs for stroke and traumatic brain injury patients. A few of its clinics run kinesiology and vestibular therapy programs, concussion management and baseline testing, and even trauma-informed yoga and meditation aimed at recovery from brain injury and PTSD.

The manufacturing side develops health and wellness products tied to that same clinical work, though it’s the smaller of the two segments by revenue.

The Stock’s Journey: Nasdaq, Reverse Splits, and Delisting

NVOS has had a rough few years, and understanding the timeline explains a lot about where the stock sits today.

The company uplisted to the Nasdaq Capital Market on February 23, 2021, after carrying out a 1-for-10 reverse split to meet Nasdaq’s minimum price requirement. For a while, that uplisting looked like a real turning point. Then things unraveled. In January 2023, Novo received a Nasdaq notice for failing to file its annual and quarterly reports on time, and by August 2023 the stock had fallen roughly 92% from its 52-week high.

In September 2023, the board authorized a $5 million stock buyback, seemingly a vote of confidence. Weeks later, on November 6, 2023, Novo executed a second 1-for-10 reverse split to fix its bid price problem again. The stock dropped more than 50% in a single day anyway, since a reverse split changes the share count, not the company’s underlying value.

The final blow came on November 4, 2024, when Nasdaq notified Novo that its common stock would be delisted for failing to maintain the minimum bid price, with trading suspended two days later. NVOS now trades over the counter.

If you want the fuller play-by-play, there’s a detailed volatility analysis and a comprehensive company overview that dig further into what went wrong.

NVOS Stock Snapshot

As of the latest data, NVOS trades on the OTC market at a fraction of a cent, with a market capitalization in the tens of thousands of dollars rather than millions. That’s a direct result of the two reverse splits and the Nasdaq delisting.

For a closer look at where the price sits right now, check the current NVOS price page or the latest stock forecast. There’s also a separate price target breakdown if you want analyst-style projections.

Why the Stock Fell So Far

A few things stack up here. Novo has posted consistent net losses even as revenue held in the low double-digit millions, which puts pressure on cash reserves. Compliance issues with Nasdaq’s filing deadlines didn’t help investor confidence, and two reverse splits in under three years are usually a signal that a company is fighting to stay listed rather than growing into a higher share price. Once the delisting happened, institutional interest and daily trading volume dried up further, which is typical for OTC-listed healthcare micro-caps, visit more.

The company has also explored various financing arrangements over the years, including debt instruments meant to shore up its balance sheet, though these plans have had mixed follow-through.

What Retail Investors Are Saying

NVOS still has an active following among retail traders, mostly on message boards and social platforms where people track penny stocks for potential rebounds. If you want a sense of current sentiment, the Reddit discussion roundup and the Stocktwits sentiment page are worth a scan before you form an opinion either way.

A Note on Novosanis

One detail that comes up often in NVOS research is Novosanis, a diagnostics-focused company Novo has had ties to in the biotech space. If that connection interests you, there’s a separate piece on Novosanis and its role in the biotech sector that covers it in more depth.

Should You Watch NVOS?

That depends entirely on your risk tolerance. Sub-penny OTC stocks like NVOS can move fast in both directions on small volume, and the company’s history of reverse splits and a Nasdaq delisting are the kind of red flags that make this a speculative watch rather than a buy-and-hold candidate for most investors. 

None of this is financial advice, and if you’re seriously considering a position, it’s worth reading the company’s actual SEC filings rather than relying on any single article, including this one.

FAQs

What does Novo Integrated Sciences Inc actually do? 

It runs healthcare clinics across Canada and the U.S. offering physiotherapy, chiropractic care, occupational therapy, and specialized rehab services, alongside a smaller product manufacturing arm.

Is NVOS still listed on Nasdaq? 

No. Nasdaq delisted the stock in November 2024 after it failed to meet the minimum bid price requirement. It now trades on the OTC market.

Why has NVOS done two reverse splits? 

Both splits, in 2021 and 2023, were attempts to raise the per-share price above Nasdaq’s minimum bid requirement. Neither fix held for long.

Is Novo Integrated Sciences profitable? 

No. The company has reported net losses in recent years despite bringing in revenue in the low double-digit millions.

Where is Novo Integrated Sciences headquartered? 

Bellevue, Washington, with clinical operations extending into Canada.

Is NVOS a good investment? 

That’s a personal call based on your own risk tolerance. As a sub-penny OTC stock with a history of reverse splits and a Nasdaq delisting, it carries meaningfully more risk than a typical listed healthcare stock. This isn’t investment advice.

Conclusion

Novo Integrated Sciences Inc went from a Nasdaq-listed healthcare rollup with real clinical operations to a sub-penny OTC stock in the space of about three years. The underlying business, physiotherapy and rehab clinics plus a product development arm, still exists and still generates revenue, but the balance sheet losses, the repeated reverse splits, and the 2024 delisting tell a story of a company that’s struggled to convert clinical operations into a stable public listing. Anyone tracking NVOS should keep an eye on upcoming filings and any financing news, since those are usually what move this stock the most.